Exhibit 99.1 Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update -- Cash Position of $307 Million Provides Stable and Strong Capital Foundation -- -- Total Net Revenue of $68 Million ($124 Million Year-To-Date) Reflecting Continuing Efforts to Maximize VASCEPA/VAZKEPA Performance Globally -- -- Leadership Transition Completed with Appointment of Aaron Berg as President and CEO -- DUBLIN, Ireland and BRIDGEWATER, N.J., July 31, 2024 -- Amarin Corporation plc (NASDAQ:AMRN), today ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-21392 Amarin Corporation plc (Exact Name of Registrant as Specified in its Charter) England and Wales Not applicable (State or Other Jurisdicti ...

-- Cash Position of $307 Million Provides Stable and Strong Capital Foundation –-- Total Net Revenue of $68 Million ($124 Million Year-To-Date) Reflecting Continuing Efforts to Maximize VASCEPA/VAZKEPA Performance Globally -- -- Leadership Transition Completed with Appointment of Aaron Berg as President and CEO -- DUBLIN and BRIDGEWATER, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today reported financial results for the second quarter ended June 30, 2024, and provided a b ...

-- Cash Position of $307 Million Provides Stable and Strong Capital Foundation –-- Total Net Revenue of $68 Million ($124 Million Year-To-Date) Reflecting Continuing Efforts to Maximize VASCEPA/VAZKEPA Performance Globally -- -- Leadership Transition Completed with Appointment of Aaron Berg as President and CEO -- DUBLIN and BRIDGEWATER, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today reported financial results for the second quarter ended June 30, 2024, and provided a b ...

Uncovering affordable breakthrough stocks under $10 in the portfolio can lead to high-price return opportunities. Here, the focus is on three such stocks, each demonstrating strong fundamentals that signal high upside potential.The first company’s top prospects include continued revenue growth, significant improvements in gross margins and successful strategic expansions. These position the company for robust future performance in the environmentally sustainable carbon products sector.On the other hand, the ...

Core Insights - The Portuguese Ministry of Health has approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce cardiovascular event risks in high-risk patients [1] - This approval represents the eighth national reimbursement of VAZKEPA in Europe, enhancing its market presence [1] - The commercialization of VAZKEPA in Portugal will commence on August 1, 2024, providing a new treatment option for patients with established cardiovascular disease [1] Company Overview - Amarin Corporation is focused on innovative pharmaceutical solutions for cardiovascular disease management, with a commitment to addressing cardiovascular risks beyond traditional therapies [1] - The company has a strong intellectual property position for VAZKEPA in Europe, extending until 2039 [1] - Amarin is actively pursuing pricing and reimbursement discussions in other European markets to enhance patient access [1] Market Context - In Portugal, the prevalence of established cardiovascular disease among adults aged 45 to 79 is reported at 10.7% [1] - Cardiovascular disease accounts for over 35,000 annual deaths in Portugal, representing 29% of total mortality in 2017 [1] - The growing prevalence of cardiovascular risk factors underscores the urgent need for effective treatment options in the Portuguese healthcare system [1]

DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed by Q&A on Wednesday, July 31st, 2024, at 8:00 a.m. ET. The conference call with management will follow the release of the Company’s second quarter 2024 financial results in the pre-market hours on July 31st.   To enhance engag ...

-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- -- EddingPharm Now Working to Prepare for National Reimbursement and Drug Listing (NRDL) and Enhance the Commercial Launch of VASCEPA Across Mainland China -- DUBLIN and BRIDGEWATER, N.J., July 08, 2024 (GLOBE NEWSWIRE) -- Amari ...

Core Viewpoint - Amarin Corporation's commercial partner EddingPharm has received regulatory approval from China's National Medical Products Administration (NMPA) for VASCEPA to reduce the risk of cardiovascular events in specific high-risk adult patients [1][2] Group 1: Regulatory Approval and Market Potential - VASCEPA is approved as an adjunct to statin therapy for adult patients with elevated triglyceride levels (≥150 mg/dL) and established cardiovascular disease or diabetes with additional risk factors [1][2] - EddingPharm is working to include VASCEPA in the National Reimbursement Drug Listing (NRDL), which covers 98% of the Chinese population, allowing for public reimbursement [2] Group 2: Cardiovascular Disease Context in China - Cardiovascular disease (CVD) accounts for 44-47% of all deaths in China, with an estimated 330 million patients suffering from CVD [3] - The World Heart Federation projects a 50% increase in cardiovascular events in China from 2010 to 2030 due to population aging and growth [3] Group 3: Financial Implications and Partnerships - Amarin will receive a regulatory milestone payment of $15 million from EddingPharm following the NMPA approval [4] - EddingPharm will pay Amarin tiered double-digit percentage royalties on net sales of VASCEPA in China [4] Group 4: Future Developments - NMPA has requested EddingPharm to conduct a post-approval study to verify VASCEPA's efficacy in reducing cardiovascular events in Chinese patients [3][4]

Bangkok, Thailand, June 07, 2024 (GLOBE NEWSWIRE) -- LA BOUTIQUE This new location promises to be a premier destination for high-end fashion enthusiasts and tourists visiting Bangkok, Thailand. Celebrating 12 years in the fashion industry, LA BOUTIQUE has consistently pushed the boundaries of design and innovation, creating timeless pieces that captivate audiences worldwide. The brand’s exquisite collections have been worn by international celebrities such as Eva Longoria, Olivia Palermo, and Kristina Baza ...